*  Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in...

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). Primary Purpose: Treatment. Official Title:. ... Secondary Outcome Measures: *Safety and Tolerability [ Time Frame: 10 weeks ]. Standard Measurements (e.g. AEs, ECG, Labs, PE ... Primary Outcome Measures: *Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]. Primary Endpoint: Agitation/Aggression ... This is a multicenter, randomized, double-dummy, double-blind, placebo-controlled study, consisting of 10 weeks of treatment. ...
https://clinicaltrials.gov/ct2/show/study/NCT01584440

*  Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo - Full Text View - ClinicalTrials.gov

Primary Outcome Measures: *Clinical response assessed at end of therapy visit. Clinical success defined by the need for no ... additional antibiotic treatment. [ Time Frame: 7 Days ]. Secondary Outcome Measures: *Clinical response assessed at follow up ... Primary Purpose: Treatment. Official Title:. An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety ... September 2005 (Final data collection date for primary outcome measure). Intervention Details: Drug: SB-275833 ointment, 1% ...
https://clinicaltrials.gov/ct2/show/study/NCT00133874?show_locs=Y

*  The Adult Antiretroviral Treatment and Resistance Study (Tshepo) - Full Text View - ClinicalTrials.gov

Secondary Outcome Measures: *Time to drug resistance, rates of point mutations at virological failure, adherence to study ... Specifically, treatment follow-up via the Standard of Care, the national standard of care as it evolves in Botswana, with ... The 'Adult Antiretroviral Treatment and Resistance Study,' hereafter referred to as 'The Tshepo Study,' is the first large- ... The Adult Antiretroviral Treatment and Resistance Study (Tshepo). This study has been completed. ...
https://clinicaltrials.gov/show/NCT00197613?order=148

*  PRET: Patients Prone to Recurrence After Endovascular Treatment - Full Text View - ClinicalTrials.gov

Masking: Double (Participant, Outcomes Assessor). Primary Purpose: Treatment. Official Title:. PRET: Patients Prone to ... Secondary Outcome Measures: *safety data (mortality rate, number of adverse events, and severity of adverse events) [ Time ... The anatomy of the lesion is such that endovascular treatment is possible with both types of coils (not necessarily certain or ... The PRET study aims at comparing two types of coils used in the endovascular treatment of intracranial aneurysms. The first ...
https://clinicaltrials.gov/ct2/show/NCT00626912?recr=Open&cond="Intracranial Aneurysm"&rank=14

*  Neurocognitive Effects of Opiate Agonist Treatment - Full Text View - ClinicalTrials.gov

Primary Outcome Measures: *Global Neurocognitive Function [ Time Frame: 2 and 4 months ]. Metrics:. A Global Deficit Score (GDS ... The purpose of this study is to (1) compare the effects of buprenorphine and methadone, two types of opioid addiction treatment ... Neurocognitive Effects of Opiate Agonist Treatment (NEO). This study has been completed. ... Please see list of component test measures under the Domain-Specific Neurocognitive Function outcome). ...
https://clinicaltrials.gov/ct2/show/NCT01733693?term=" November 14, 2012":" December 14, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]&rank=3

*  Vestibular Function Outcome After Cartilage Cap Occlusion Surgery - Full Text View - ClinicalTrials.gov

Primary Purpose: Treatment. Official Title:. Objective Assessment of Vestibular Function Outcome After Cartilage Cap Occlusion ... Primary Outcome Measures: *objective improvement [ Time Frame: baseline to 3 months ]. The primary outcome measure will be the ... Secondary Outcome Measures: *ABC Scale [ Time Frame: baseline to 3 months ]. Secondary objective outcome measures will be ... Vestibular Function Outcome After Cartilage Cap Occlusion Surgery. This study has been withdrawn prior to enrollment. ...
https://clinicaltrials.gov/ct2/show/NCT01727544?recr=Open&cond="Dizziness"&rank=11

*  A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection - Full...

Primary Outcome Measures: *Virologic: A. Plasma viral load B. Tissue viral load (CNS, lymphoid tissues, genital tract) C. HIV ... A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection. This ... Primary Purpose: Treatment. Official Title:. Randomized, Controlled, Open Label, Multi-Center Phase III Trial Comparing the ... Within these treatment arms, they are stratified according to a positive or negative p24 antigen result. At Week 16, patients ...
https://clinicaltrials.gov/ct2/show/NCT00006154?term="Acute Infection" [CONDITION] AND HIV [CONDITION]&rank=12

*  Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis - Full...

Masking: Single (Outcomes Assessor). Primary Purpose: Treatment. Official Title:. An Open-label, Multi-center, Randomized, ... Vectical™ Ointment treatment, twice daily on weekdays (Mon - Fri) and Clobex® Spray treatment twice daily on weekends (Sat - ... Subjects with a wash-out period for systemic treatment less than 12 weeks (corticosteroids, biologics and/or PUVA treatment; ... Subjects receiving treatment with beta-blockers or lithium, whose dose has been stable for at lest 6 months and who have shown ...
https://clinicaltrials.gov/ct2/show/NCT00988637

*  Olanzapine Versus Comparator in the Treatment of Bipolar Disorder - Full Text View - ClinicalTrials.gov

Primary Outcome Measures: *Investigate the efficacy of olanzapine once a day orally for 4 weeks to Lithium Carbonate orally in ... Primary Purpose: Treatment. Official Title:. Olanzapine Versus Lithium Carbonate in the Treatment of Bipolar Disorder, Manic or ... Treatment with clozapine within 4 weeks prior to visit 2. Treatment with other antipsychotic drugs or mood stabilizers within 2 ... Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the ...
https://clinicaltrials.gov/ct2/show/NCT00485680

*  Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias - Full...

Primary Outcome Measures: *Rate of complete response (CR) in all patients at 3rd month. ... Secondary Outcome Measures: *Duration of response (CR). *Overall survival at 12th month. ... Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias. The ... Open Label Pilot Phase II Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and ...
https://clinicaltrials.gov/ct2/show/NCT00276926?cond="PDGFRA-associated chronic eosinophilic leukemia" OR "Hypereosinophilic Syndrome"&rank=1

*  CorpusUL: Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated...

Objectives: This study sought to examine the relationship between left ventricular mass (LVM) regression and clinical outcomes after transcatheter aortic valve replacement (TAVR). Background: LVM regression after valve replacement for aortic stenosis is assumed to be a favorable effect of LV unloading, but its relationship to improved clinical outcomes is unclear. Methods: Of 2,115 patients with symptomatic aortic stenosis at high surgical risk receiving TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) randomized trial or continued access registry, 690 had both severe LV hypertrophy (left ventricular mass index [LVMi] 149 g/m2 men, 122 g/m2 women) at baseline and an LVMi measurement at 30-day post-TAVR follow-up. Clinical outcomes were compared for patients with greater than versus lesser than median percentage change in LVMi between baseline and 30 days using Cox proportional hazard models to evaluate event rates from 30 to 365 days. Results: ...
corpus.ulaval.ca/jspui/handle/20.500.11794/7168

*  CorpusUL: Open issues in transcatheter aortic valve implantation. Part 1 : patient selection and treatment strategy for...

An exponential increase in the use of transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis has been witnessed over the recent years. The current article reviews different areas of uncertainty related to patient selection. The use and limitations of risk scores are addressed, followed by an extensive discussion on the value of three-dimensional imaging for prosthesis sizing and the assessment of complex valve anatomy such as degenerated bicuspid valves. The uncertainty about valvular stenosis severity in patients with a mismatch between the transvalvular gradient and the aortic valve area, and how integrated use of echocardiography and computed tomographic imaging may help, is also addressed. Finally, patients referred for TAVI may have concomitant mitral regurgitation and/or coronary artery disease and the management of these patients is discussed ...
corpus.ulaval.ca/jspui/handle/20.500.11794/7268

*  Early Postoperative Complications of the Ex-PRESS Implantation versus Trabeculectomy: A Randomized Clinical Trial. | IOVS |...

Purpose : We aimed to compare early postoperative complications between trabeculectomy and Ex-PRESS implantation.. Methods : Enrolled patients with primary open-angle or exfoliative glaucoma were randomly assigned to receive trabeculectomy (trabeculectomy group) or Ex-PRESS implantation (Ex-PRESS group) (FIGURE 1). Primary outcomes were early postoperative complications, including postoperative anterior chamber inflammation, frequencies of hyphema, flat anterior chamber, choroidal detachment, hypotonic maculopathy, and visual acuity. Secondary outcomes were open anterior chamber duration during surgery, postoperative intraocular pressure, postoperative anti-glaucoma medications, frequencies of laser suture lysis and bleb needling, and the relationship between iris contact with the Ex-PRESS tube and anterior chamber depth in the Ex-PRESS group.. Results : Sixty-four patients were divided between the groups. The Ex-PRESS group had significantly lower flare values between 7 ...
iovs.arvojournals.org/article.aspx?articleid=2558520

*  ACS: A triad of troubles sets the stage for MI : Nursing made Incredibly Easy

ECG changes with NSTEMI are the same as with UA; however, cardiac biomarkers are positive. Elevated cardiac biomarkers indicate that plaque disruption has occurred with significant myocardial injury or infarct (necrosis).. The patient will likely undergo nonemergent diagnostic cardiac catheterization with possible percutaneous coronary intervention (PCI), such as angioplasty and/or stent placement. According to the American College of Cardiology (ACC) Foundation/American Heart Association (AHA) Taskforce on Practice Guidelines/Society for Cardiovascular Angiography and Interventions 2011 Guideline for Percutaneous Coronary Intervention, PCI to improve survival is reasonable in patients with UA/NSTEMI when an unprotected left main coronary artery is the culprit lesion and the patient isn't a candidate for coronary artery bypass grafting (CABG).. STEMI is confirmed when chest pain and associated symptoms occur with the presence of ST-segment elevation. STEMI indicates that plaque disruption has ...
journals.lww.com/nursingmadeincrediblyeasy/Fulltext/2012/11000/ACS__A_triad_of_troubles_sets_the_stage_for_MI.5.aspx

*  Percutaneous Coronary Interventions Registry | Division of Cardiology | Albert Einstein College of Medicine

Einstein-Montefiore is one of [INSERT #] academic medical centers across the nation participating in the Percutaneous Coronary Interventions Registry.. Major advances have occurred in diagnostic techniques and treatment procedures (coronary revascularization and surgery) for patients with ischemic heart disease. These advances have resulted better diagnoses, better selection of patients for surgery or catheter-based interventions versus medical management, and increased survival rates. However, as the American population ages, rates of co-morbidity (including peripheral vascular disease, metabolic disorders, cerebrovascular disease) and association of coronary and valvular diseases increase. As a result, practicing interventionalists and cardiologists are experiencing greater problem detecting and treating combined coronary and valvular diseases.. The PCI Registry provides participating physicians with a quality control tool to accomplish the following:. ...
einstein.yu.edu/departments/medicine/divisions/cardiology/patient-care/interventional-cardiology/pci-registry.aspx

*  Predictors of Proximal Aortic Dissection at the Time of Aortic Valve Replacement | Circulation

Sixteen variables were assessed in each patient. These included (1) age at the time of AVR, (2) sex, (3) cardiac functional class (New York Heart Association), (4) reduced left ventricular ejection fraction (,25%), and (5) an angiographic diagnosis of coronary heart disease, as derived from preoperative medical records. The type of aortic valve disease was categorized according to echocardiographic and/or angiographic findings as (6) aortic stenosis, (7) aortic regurgitation, or (8) a combination of both. Surgical records at AVR were used to assess (9) a congenitally bicuspid aortic valve, (10) the maximum diameter of the ascending aorta (mm), and (11) thinning or (12) fragility of the aortic wall (according to intraoperative inspection and palpation). (13) Concomitant coronary artery bypass grafting and (14) time of aortic cross-clamping (minutes) were also assessed in each patient. In 15 patients with no intraoperative measurements available at AVR (24%), images from preoperative ...
circ.ahajournals.org/content/100/suppl_2/II-287

*  Overall Survival With Everolimus in Advanced Pancreatic Neuroendocrine Tumors in the RADIANT-3 Trial - The ASCO Post

As reported by Yao et al in the Journal of Clinical Oncology, the final overall survival analysis from the phase III RADIANT-3 trial showed a median survival of 44.0 months among patients with advanced pancreatic neuroendocrine tumors initially randomized to receive everolimus (Afinitor, Zortress) treatment.. Study Details. In the trial, 410 patients with advanced progressive low- or intermediate-grade pancreatic neuroendocrine tumor were randomized to receive everolimus at 10 mg/d (n = 207) or placebo (n = 203); treatment continued until disease progression, development of unacceptable toxicity, withdrawal of consent, or primary analysis. Crossover to open-label everolimus was permitted after disease progression in the placebo group. The trial showed a significant improvement in progression-free survival, the primary endpoint, for everolimus vs placebo. After the primary analysis, all patients continuing in the study were unblinded and rolled over into an open-label ...
ascopost.com/News/43940

*  Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma

Thirty-six patients (43.4%) had 3 cycles of chemotherapy, whereas 21 (25.3%) had more than 3. Progression to chemotherapy was observed in 10.9% (9 of 83) of patients, partial response in 30.1% (25 of 83) and stable disease in 59% (49 of 83). Sixty-three patients underwent extrapleural pneumonectomy. Fifty-five patients (87.3%) had epithelial tumour. Forty-two patients (66.7%) were in pathological Stage 3. Major complications after extrapleural pneumonectomy were observed in 28 patients (44.4%), whereas 30-day postoperative mortality was 11.1% (7/63). Radiotherapy was not administered in 24 patients (38.1%) due to major complications after surgery or patient intolerance. Two patients (3.2%) died within 90 days after the end of radiotherapy. The trimodality treatment was completed in 37 (44.6%) patients. Median overall survival was 35.6 months, with 1- and 3-year overall survival of 82% and 48% for patients who completed the trimodality treatment compared with 32% and 14% for ...
mesothelioma-line.com/2017/05/19/induction-chemotherapy-extrapleural-pneumonectomy-and-adjuvant-radiotherapy-for-malignant-pleural-mesothelioma/

*  HKU Scholars Hub: Atrial fibrillation after esophagectomy is a marker for postoperative morbidity and mortality

Objective: Postoperative atrial fibrillation complicates recovery in 20% to 25% of patients after esophagectomy for cancer. The purpose of this study is to understand this phenomenon. Methods: Between 1982 and 2000, 198 (22% of 921) patients had postoperative atrial fibrillation after esophagectomy. Propensity scoring and the Greedy Match algorithm were used to develop a cohort of control patients for statistical comparisons. One hundred forty-four patients who had postoperative atrial fibrillation were matched. Results: Pulmonary complications affected 42% of patients in the atrial fibrillation group compared with 17% in the control group (P < .001). Anastomotic leakage was more common in the atrial fibrillation group (6.9% vs 1.4%, P = .035). Surgical sepsis migrated with atrial fibrillation 4 times more frequently (P = .001). Multivariate analysis demonstrated that postoperative pulmonary complications (odds ratio, 2.5; 95% confidence interval, 1.42-4.3) and surgical sepsis (odds ratio, 3.4; ...
hub.hku.hk/handle/10722/83776

*  Highlights in Advanced Prostate Cancer From the 2012 ASCO Genitourinary Cancers Symposium - Hematology & Oncology

New York, New York. An Analysis to Quantify the Benefit of Sip-T Accounting for the Crossover in the Control Arm of the IMPACT Study. Three phase III trials have demonstrated a longer overall survival (OS) with sipuleucel-T in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC) compared to controls who received nonactivated autologous cell products.1-3 However, the results of these trials may have been confounded by the option for patients in the control arm who experienced disease progression to receive salvage therapy with APC8015, an autologous immunotherapy made from cells cryopreserved at the time of control generation. A previous analysis of data from the 3 phase III trials suggested that crossover treatment may have prolonged OS in the control arm (hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.37-0.73; P=.0001).4 However, patients in the control arm who received the crossover treatment had more favorable ...
hematologyandoncology.net/supplements/470/

*  Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia - Full Text...

The first study is a pilot study and will act as proof of principle. This first study will include 20 patients divided into 2 groups on the basis of a randomized controlled trial: 10 patients in the control group receiving conventional treatment and 10 patients receiving therapeutic phlebotomy to lower blood viscosity. The objective is to evaluate the effect of controlled phlebotomy in patients with Grade 3, Category 5 or 6 chronic critical limb ischemia having tissue loss on Rutherford classification (Fontaine stage IV), end-stage peripheral vascular disease resistant to maximal medical therapy and where revascularization therapy (both percutaneous and surgical) has either proved insufficient or is contra-indicated or declined by the patient, usually resulting in amputation.. The primary outcome parameters will be: the salvage rate of the limb as compared with the salvage rate of the limb with conventional therapy.. Objective classification of improvement in perfusion of ...
https://clinicaltrials.gov/ct2/show/NCT01758874

*  Institute of Cancer Research Repository - The Optimal Duration of Adjuvant Endocrine Therapy for Early Stage Breast Cancer...

Adjuvant endocrine therapy has made a significant impact in improving overall survival for women with hormone receptor (HR)-positive breast cancer. The anti-estrogen tamoxifen is the most widely used therapy, although in postmenopausal women, aromatase inhibitors (AIs) have further improved outcomes either as an alternative to tamoxifen for 5 years, or given in sequential fashion following initial tamoxifen therapy. However, late recurrence remains perhaps the biggest risk in HR-positive breast cancer, with more than half all recurrences occurring beyond 5 years since primary diagnosis. As such, the current debate is whether extended AI or prolonged tamoxifen therapy should be given, and if so, to whom. We review some of the recent studies that have addressed this question and demonstrated further reduction in risk of recurrence, and discuss the clinical issues that face women and their health care providers in determining who should use which drug, and for how long.. ...
publications.icr.ac.uk/13256/

*  The impact of aerobic fitness on functioning in chronic back pain

Despite lack of convincing evidence that reduced aerobic fitness is associated with chronic back pain (CBP), exercise programs are regarded as being effective for persons with non-specific CBP. It is unsure whether gain in aerobic fitness following intervention is associated with functioning improvement in persons with CBP. The objective of this prospective cohort study was to study the impact of aerobic fitness on functioning in persons with CBP, at baseline and following 3-week intensive interdisciplinary intervention. This study included persons who had passed 8 weeks of sick-listing because of back pain (n = 94) and were referred to a 3-week intensive biopsychosocial rehabilitation program. Aerobic fitness was assessed with a sub-maximal bicycle test at baseline, at admission to and discharge from the rehabilitation program, and at 6 months follow-up. Contextual factors, body function, activity and participation were evaluated before and after intervention. In addition, working ability was ...
dare.ubvu.vu.nl/handle/1871/11460

*  Abstract 12609: Intracardiac Echo Findings Post Atrial Fibrillation Ablation Are an Important Predictor of Late Pericardial...

Introduction: Major bleeding are serious complications of catheter ablation for atrial fibrillation (AF). Late effusions following AF ablation procedures have been recently reported.. We sought to determine whether the presence of a trivial effusion detected by intracardiac echo at the end of AF ablation procedures performed without warfarin discontinuation predicts the development of late pericardial effusion.. Methods: A total of 2618 consecutive patients undergoing catheter ablation for AF with continuous warfarin have been enrolled in this prospective registry. All ablation procedures were performed under intracardiac echocardiography (ICE) guidance. At the end of each procedure ICE was utilized to detect any degree of effusions.. Results: In 510 out of 2618 (19%) patients, trivial pericardial effusion was detected by ICE at the end of the procedure. All 2108 patients with negative ICE did not show any late pericardial effusions. On the other hand, 8 of the 510 (1.5%) patients with trivial ...
circ.ahajournals.org/content/130/Suppl_2/A12609

*  BRCA1 Gene Mutation Associated with Neoadjuvant Chemotherapy | MD Anderson Cancer Center

Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response(pCR) - the disappearance of all evidence of disease from the breast tissue and lymph nodes - regardless of disease stage after standard neoadjuvant chemotherapy, according to new research from The University of Texas MD Anderson Cancer Center.. The study, published online in The Journal of Clinical Oncology on September 6, is the largest study to date to find that the pCR rate is significantly higher in BRCA1 carriers (46 percent) than in women carrying the BRCA2 mutation (13 percent) and non-carriers (22 percent). Among all the women, researchers did not find a statistical difference in overall survival rates, but noted that BRCA1 carriers who achieved a pCR had better five-year, relapse-free survival and overall survival rates.. BRCA1 and BRCA2 belong to a class of human genes known as tumor suppressors. The mutation is inherited and increases a woman's chance of developing breast ...
https://mdanderson.org/newsroom/2011/09/brca1-gene-mutation-associated-with-neoadjuvant-chemotherapy.html

*  Long-term prognosis of chronic kidney disease in non-ST elevation acute coronary syndrome treated with invasive strategy

Multivariate analysis confirmed that the baseline CKD was an independent predictor of combined event risk (HR: 1.66; 95% CI: 1.05-2.61; p=0.03), comparable to the value associated with diabetes mellitus. In 82.7% of the cases, renal function remained stable during hospitalization. The correlation between baseline values and creatinine clearance showed a Spearman coefficient of ρ=0.77; p,0.0001.. Discussion. In our population of patients with NSTE-ACS with invasive treatment, there were a 27% of cases with CKD on admission. This is similar to the one observed by others based on patients treated with catheterization15,24 but lower than that of large NSTE-ACS registries.4 We have observed a higher rate of ACVE in cases with CKD patients, with a long-term absolute increase in risk of 21%.. As in other studies5,15,24 there is a reduced frequency of active smoking in the CKD group. This figure may be related to the higher number of hospital admissions for ischemic heart disease and heart failure, ...
nefrologiadigital.revistanefrologia.com/en-publicacion-nefrologia-articulo-long-term-prognosis-chronic-kidney-disease-in-non-st-elevation-acute-coronary-S2013251417301116

*  Current Status of Endovascular Stroke Treatment | Circulation

Endovascular therapy for patients with acute ischemic stroke is currently an area of intense investigation. An Accreditation Council for Graduate Medical Education-approved training pathway was developed to train physicians for endovascular treatment of cerebrovascular diseases, including ischemic stroke.28 Training criteria and standards of performance for endovascular stroke treatment are summarized in a consensus document.17,29 The American Stroke Association has given qualified endorsement of intra-arterial fibrinolysis, despite its lack of scientifically proven efficacy in ,1 trial. Intra-arterial fibrinolysis has been studied in several randomized trials and numerous case series but proven according to FDA standards in only 1 trial using prourokinase, a drug no longer available.4 Thus, intra-arterial fibrinolysis has the status of community standard in many locales, but remains an off-label application of any available fibrinolytic agent requiring further experimental ...
circ.ahajournals.org/content/123/22/2591.full

*  Polyunsaturated Fatty Acids for Adjunctive Treatment of Refractory Epilepsy - Full Text View - ClinicalTrials.gov

Polyunsaturated Fatty Acids for Treatment of Refractory Epilepsy. ABSTRACT. Objective: The primary objective of the study is to determine whether polyunsaturated fatty acids (PUFA) can be used safely and effectively as a treatment for epilepsy.. Background: Patients with intractable epilepsy are often on more than one medication and experience intolerable side effects. Fatty acids have been shown to be protective against seizures in animal models, but there is little human data. Recently, however, a small case series of patients with intractable epilepsy provided evidence of an anti-seizure effect without major side effects. There are no controlled trials of PUFA in humans.. Design/Methods: Patients with uncontrolled partial or generalized epilepsy characterized by at least 4 seizures/month will be randomized to placebo vs. PUFA in a double-blind fashion. Subjects will remain on their current drug(s) while a 4-week baseline seizure count occurs. Dosage will then be titrated ...
https://clinicaltrials.gov/show/NCT00299533

*  Responsiveness to anti-tumour necrosis factor α therapy is related to pre-treatment tissue inflammation levels in rheumatoid...

Objective: The response of rheumatoid arthritis (RA) patients to treatment with neutralising antibodies to tumour necrosis factor α (TNFα) is highly variable. The underlying mechanism for therapy responsiveness is currently unknown. We therefore evaluated the relationship between baseline molecular profiles of synovial tissues from RA patients and the clinical response to treatment with infliximab.. Methods: Synovial biopsies were obtained by arthroscopy from 18 RA patients with active disease (28 joint count Disease Activity Score (DAS28)⩾3.2) before initiation of treatment with infliximab. All patients were on stable methotrexate treatment. Clinical response at 16 weeks was defined as a reduction in DAS28 of ⩾1.2, non-response as reduction in DAS28 ,1.2. Large-scale gene expression profiling using microarrays was performed on synovial tissue samples. To identify biological processes in synovial biopsies that could discriminate between ...
ard.bmj.com/content/67/4/563

*  Aortic Regurgitation After Transcatheter Aortic Valve Implantation With Balloon- and Self-Expandable Prostheses | JACC:...

In this study of 394 TAVI patients treated with the MCV or ESV prosthesis predominantly through the transfemoral route, more-than mild AR after TAVI quantified by echocardiography was significantly higher with MCV by both unadjusted and propensity-adjusted analysis. Consequently, device success as defined by VARC was higher with the ESV. These differences were consistent when AR was assessed by angiography. Both more-than-mild AR after TAVI and device failure were related to a significant increase in mortality within 1 year after TAVI.. The MCV and ESV are the most commonly used transfemoral devices in Europe. The development of AR following TAVI is multifactorial and depends on several factors related to the aortic root anatomy and its relation to the implanted prosthesis. These include the shape and size of the annulus, degree of annular and leaflet calcification, prosthesis/annulus discongruence, and LVOT anatomy (10,17,18). In addition, specific device-related factors may also have an ...
interventions.onlinejacc.org/content/7/3/284

*  One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de...

Effectiveness was assessed by using the composite of 12 month MACE, which were all-cause death, non-fatal myocardial infarction, and target lesion revascularisation (either surgical or percutaneous). With respect to costs, the analysis was limited to the direct medical costs. The balance between costs and effects after 12 months was assessed by computing the incremental cost effectiveness ratio (the average one year costs per patient treated with drug eluting stents minus the average one year costs with bare stent implantation divided by the percentage change in MACE-free survivors after one year).. For cost effectiveness, two scenarios were investigated. The first scenario reflects the actual protocol driven resource use and effectiveness observed in the RAVEL study (which included a six month angiogram). For the estimation of the costs and effects of this scenario, we used methods similar to those used in the assessments of costs and effects in the BENESTENT II study,4 the DEBATE (Doppler ...
heart.bmj.com/content/91/4/507.full

*  CARG: Coronary Artery Rehabilitation Group Blog: Bone marrow stem cells give 'some' heart healing

Bone marrow stem cell therapy offers "moderate improvement" to heart attack patients, according to a large UK review of clinical trials. The analysis by the Cochrane Collaboration looked at 33 trials involving more than 1,700 patients. It said longer-term studies were needed to see if the experimental therapy affected life expectancy. The review comes a day after doctors reported the first case of using heart cells to heal heart attack damage. If a patient survives a heart attack, dead heart muscle is replaced with scar tissue - leaving the patient weaker and possibly on a lifetime of medicine. Researchers are beginning to show that taking cells from a heart, growing millions of new heart cells in the laboratory and pumping those back into the heart may reduce scar tissue and lead to new heart muscle. However, the trials are at a very early stage and in only a handful of patients. Using a similar technique with cells taken from the bone marrow, which is a prime source of stem cells, has a much ...
cargsaskatoon.blogspot.com/2012/02/bone-marrow-stem-cells-give-some-heart.html

*  Doppler Endpoints Balloon Angioplasty Trial Europe | definition of Doppler Endpoints Balloon Angioplasty Trial Europe by...

Looking for online definition of Doppler Endpoints Balloon Angioplasty Trial Europe in the Medical Dictionary? Doppler Endpoints Balloon Angioplasty Trial Europe explanation free. What is Doppler Endpoints Balloon Angioplasty Trial Europe? Meaning of Doppler Endpoints Balloon Angioplasty Trial Europe medical term. What does Doppler Endpoints Balloon Angioplasty Trial Europe mean?
medical-dictionary.thefreedictionary.com/Doppler Endpoints Balloon Angioplasty Trial Europe

*  Hinge Motion and Excessive Negative Remodeling as a Cause of Early Saphenous Vein Graft Failure | JACC: Cardiovascular...

A 56-year-old male patient underwent a coronary artery bypass graft operation (CABG) using the left internal thoracic artery and saphenous vein graft (SVG) for severe coronary artery disease. Fourteen months later, he was admitted to our hospital because of recurrent angina. A coronary angiogram revealed that the mid-segment of the SVG was adhered to the sternum, and significant stenosis was observed at the distal end of the adhered segment (Fig. 1, left, Online Video 1), where hinge motion was apparent. Intravascular ultrasound (Atlantis SR Pro, 40-MHz, Boston Scientific, Natick, Massachusetts) showed a minimal amount of plaque burden with excessive negative vessel remodeling at the stenotic lesion (Fig. 1A to 1C, right, Online Video 2). The lesion was successfully treated using a bare-metal stent under gradual (step-by-step) balloon inflation to avoid SVG perforation without the use of distal protection. ...
interventions.onlinejacc.org/content/6/3/e15

*  FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients - Full Text View ...

Premenopausal women with hormone receptor positive tumors must receive tamoxifen 20 mg daily for 5 years, after the end of chemotherapy.. Postmenopausal women with hormone receptor positive tumors are allowed to receive aromatase inhibitors as initial adjuvant hormone therapy or after tamoxifen.. All patients with breast conservative surgery must receive radiotherapy.. Estimated 5-year disease-free survival in the control arm (FAC x 6) is expected to be 80%. It is expected that disease-free survival will increase by 5% in the experimental arm (FAC-paclitaxel). 906 patients per arm must be recruited, to detect this difference with an alpha error of 0.05 and 80% power. Assuming a 6% post-randomization drop-out rate, 960 patients per arm are needed, 1920 in total. ...
https://clinicaltrials.gov/show/NCT00129389